Radiation Oncology

Theranostics, a technique that combines traditional medication with diagnostics, is “limitless,” according to Brandon Mancini, MD, MBA, FACRO.

Based on the prevalence of GLP-1 agonists employed in standard medical practice, Li’s team will assess their impact on radiotherapy for prostate cancer.

J. Isabelle Choi, MD, outlined evidence-based strategies for radiation dose escalation in locoregionally advanced breast cancer.

Experts discuss new modalities such as HPV vaccines, balancing hope with realism, and other considerations in cervical cancer management.

Throughout 2026, CancerNetwork® and the journal ONCOLOGY® will be dedicated to sharing the most critical developments in the radiation oncology field.

Host Brandon Mancini, MD, MBA, FACRO, introduces a special podcast series focused on delivering key insights and takeaways in the radiation oncology space.

ACT5 of the PLAT study found radiotherapy dose escalation did not improve outcomes, safety, or QOL in patients with anal cancer.

In patients less likely to respond to neoadjuvant chemoradiation, postoperative adjuvant therapy may be a viable strategy in this ESCC group.

Data from the CRITICS-II trial support total neoadjuvant chemotherapy plus chemoradiotherapy as a preferred candidate for future study in this population.

Neoadjuvant immunotherapy plus chemotherapy did not definitively increase the risk of severe pneumonitis compared with adjuvant immunotherapy.

Investigators assessed recurrence rates between axillary lymph node dissection recipients after neoadjuvant chemotherapy vs nonrecipients.

Overall survival significantly improved with radiation plus cisplatin/paclitaxel in the phase 2 RTOG 9911 trial over a historical control cohort.

Stereotactic body radiotherapy alone may be feasible instead of immediate systemic therapy in select patients with oligometastatic cancer.

How John G. Phillips, MD, MPH, and Tennessee Oncology are aiming to expand radiation oncology access in smaller communities across Tennessee.

Sunil Dutta, MD, discusses how whole-breast radiation or systemic therapy is responsible for controlling low-volume disease.

Findings from the P-RAD trial show encouraging rates of pathologic complete response among patients who received pembrolizumab plus radiotherapy.

HRQOL scores were similar among patients who received a radical cystectomy or bladder persevering therapy for non-muscle invasive bladder cancer.

Thomas Hope, MD, asserts that legislation aimed at resolving infiltration-related AEs does not address any relevant clinical issue.

Investigators noted 1 instance of rectovaginal fistula in the PEG gel arm, although rapid postoperative recovery occurred.

Thomas Hope, MD, believes that an NRC initiative to update infiltration guidelines may organically address concerns that H.R. 2541 outlines.

In the 177Lu plus SBRT arm, the median PFS was 17.6 months vs 7.4 months in the SBRT alone arm for patients with oligorecurrent HSPC.

Thomas Hope, MD, had not observed an adverse effect attributable to an infiltration across more than a decade of administering nuclear agents at UCSF.

Deeper short-term declines in quality of life occurred when combining cisplatin with radiation for those with intermediate-risk cervical cancer.

Ron Lattanze, MBA, provided his commentary regarding why H.R.2541 or the Nuclear Medicine Clarification Act of 2025 should be passed.